Your browser version is outdated. We recommend that you update your browser to the latest version.


We have Worldwide exclusive rights to a novel TLR7 agonist that is a potent stimulator of the innate immune system. The TLR7 agonist has been GMP produced and shown good scale-up and stability properties.

We have currently demonstrated POP with our technology in preclinical models. The studies demonstrate a potent antitumor activity using both systemic and intratumoral approaches in combination with clinically used therapies.

- Combination with Radiotherapy showed complete remission in more than 70 % of mice

- Combination with chemotherapy showed a strong antitumor activity

- Combination with immune checkpoint inhibitor PD-1 treatment



Clinical development

We will initiate a clinical phase I study in patients with metastatic cancer, and extent into a phase IIA in combination treatment with existing therapies.